Our Services
Medical Information
Helpful Resources
Published on: 9/16/2026
Stopping duloxetine abruptly is not usually life threatening, but it can trigger discontinuation syndrome, with symptoms like dizziness, nausea, headache, irritability, insomnia, "brain zaps," and flu-like aches that may begin within one to three days and last one to two weeks. Risk rises with higher doses, longer treatment, and duloxetine's short half-life, and in some cases returning depression or anxiety symptoms can worsen mood or increase suicidal thoughts. Because of this, a gradual taper guided by a clinician is generally recommended rather than quitting cold turkey. There are several important factors that affect how severe your withdrawal may be, including your dose, how long you have taken it, and your other health conditions, so review the complete details below before making changes.
If you have already stopped and feel unwell, or you are unsure whether what you are experiencing is withdrawal, a relapse, or something else entirely, it helps to get clarity fast: take a free, instant online symptom check to understand your symptoms and decide whether to call your prescriber, seek urgent care, or simply monitor at home.
Last reviewed for medical accuracy: 09/15/2026
Duloxetine is a prescription medication commonly used to treat depression, generalized anxiety disorder, fibromyalgia, and certain types of chronic pain. It works by increasing levels of serotonin and norepinephrine—two key neurotransmitters—in the brain. While duloxetine can be highly effective, stopping it abruptly (“cold turkey”) can lead to unwanted and sometimes serious withdrawal effects.
When you stop taking duloxetine suddenly, your brain doesn’t have time to adapt to the change in neurotransmitter levels. This can trigger discontinuation syndrome, a cluster of physical and psychological symptoms that range from mild to severe.
Most symptoms begin within a few days of the last dose and may last one to two weeks—or longer in some cases.
Abruptly stopping duloxetine is risky because:
Neurochemical Rebound
Sudden removal causes a rebound drop in serotonin and norepinephrine, leading to withdrawal effects.
Increased Relapse Risk
Rapid discontinuation may trigger a return of depression or anxiety symptoms, sometimes more intensely than before.
Physical Discomfort
Severe dizziness, nausea, and sensory disturbances can interfere with daily life and safety (e.g., driving, operating machinery).
Emotional Instability
Mood swings, irritability, and even suicidal thoughts can emerge if you stop too quickly.
For these reasons, clinical guidelines recommend a gradual taper under medical supervision.
Always follow your doctor’s advice. A typical taper schedule might look like:
Your healthcare provider may suggest switching to a capsule that can be cut or using liquid formulations for more precise dose reductions. Never adjust your dose on your own.
Most withdrawal effects are uncomfortable but not dangerous. However, contact your doctor immediately if you experience:
If you’re unsure about any symptoms, you can do a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized insights and guidance.
These strategies may ease your transition, but they don’t replace medical supervision.
Even if you plan a gradual taper, regular check-ins with your prescriber are crucial. Call your doctor right away if you notice:
If you suspect a life-threatening reaction, such as signs of serotonin syndrome or severe dehydration, seek emergency medical care.
Your mental and physical health deserves careful attention. If you’re considering stopping duloxetine—or if you’ve already started to reduce your dose—talk to a healthcare professional to create a safe, effective taper plan. Never hesitate to seek help for anything that feels life threatening or beyond your control.
(References)
* Domperidone. 2006. PMID: 30000430.
* Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772.
* Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697.
* Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004. Epub 2021 Sep 22. PMID: 34607709.
* Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.
* Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023 May 10;5(5):CD014682. doi: 10.1002/14651858.CD014682.pub2. Epub 2023 May 10. PMID: 37160297; PMCID: PMC10169288.
* Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Jul 17;18(1):504. doi: 10.1186/s13018-023-03995-z. Epub 2023 Jul 17. PMID: 37461044; PMCID: PMC10351165.
* Yang P, Chen H, Wang T, Su H, Li J, He Y, Su S. Electroacupuncture promotes synaptic plasticity in rats with chronic inflammatory pain-related depression by upregulating BDNF/TrkB/CREB signaling pathway. Brain Behav. 2023 Dec;13(12):e3310. doi: 10.1002/brb3.3310. Epub 2023 Nov 10. PMID: 37948105; PMCID: PMC10726860.
* Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore A, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. PMID: 39367772; PMCID: PMC11474957.
* Liu D, Li N, Liu L, Qiu L, Zhou Z, Wu J. Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. J Affect Disord. 2025 Nov 1;388:119517. doi: 10.1016/j.jad.2025.119517. Epub 2025 May 27. PMID: 40441644.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.